Abstract 163P
Background
Gall Bladder Cancers(GBC) comprise a feared entity among all oncologists. Advanced stage of disease at presentation and grave prognosis despite use of all the armamentarium has led to GBC patients faring worse than other sites of malignancy.The goal of this study is to evaluate the efficacy and safety of chemotherapy alone versus radiotherapy alone in patients with locally advanced unresectable gallbladder carcinoma.
Methods
This was a randomized control study done in Regional Institute of Medical Sciences, Imphal, Manipur from 1st August 2017 to 31st July 2019. All histopathologically confirmed locally advanced unresectable carcinoma gall bladder patients were enrolled in this study. Patients who refused to give consent, metastatic disease and Child Pugh Score C were excluded. Patients who received any treatment for obstructiion was also excluded from the study. All patients were randomized into two arms. In Arm A, patients were treated with palliative chemotherapy and in Arm B patients received external beam radiotherapy. Treatment response of both radiotherapy and chemotherapy were assessed using RECIST Criteria Version1.1. Early radiation toxicity was assessed during treatment using RTOG grading. Chemotherapy toxicity was assessed using NCI-CTCAE Criteria (version 4.03). The study was carried out after obtaining approval from the Research Ethics Board. Written informed consent was taken from all the patients before enrolment of the study.
Results
Baseline characteristics of patients are listed in the table. Symptomatic response after one month of treatment in chemotherapy and radiotherapy arm were 80.7% and 61.4%. Overall response rate in chemotherapy arm was 38.4% in chemotherapy arm while 26.8% in radiotherapy arm. Median progression free survival in chemotherapy and radiotherapy arm were 7.24 vs 6.11 months (p= 0.034) respectively. Table: 163P
| Chemotherapy arm (n=30) | Radiotherapy arm (n=30) | |
| Median age | 61 years | 61 years |
| Gender | ||
| Male | 6 (20%) | 4 (13.3%) |
| Female | 24 (80%) | 26 (86.7%) |
| KPS | ||
| >80% | 13 (43.3%) | 13 (43.3%) |
| <60% | 17 (56.66%) | 17 (56.66%) |
| History of cholelithiasis | 19 (63.3%) | 20 (66.7%) |
| Clinical presentation | ||
| Jaundice | 7 (23%) | 10 (33%) |
| Abdominal pain | 6 (20%) | 7 (23%) |
| Abdominal mass | 2 (7%) | 9 (30%) |
| Ascites | 10 (33%) | 0 |
| Nausea/vomit | 5 (17%) | 4 (13%) |
| Stage | ||
| IIIA | 7 (11.7%) | 5 (8.7%) |
| IIIB | 13 (21.7%) | 12 (20%) |
| IV | 10 (16.7%) | 13 (21.7%) |
| Response | ||
| Complete response | 1 (3.8%) | 1 (3.8%) |
| Partial response | 9 (34.6%) | 6 (23%) |
| Stable disease | 11 (42.3%) | 9 (34.6%) |
| Progressive disease | 5 (19.2%) | 10 (38.4%) |
Conclusions
In advanced inoperable gallbladder cancer chemotherapy has better response rates and survival outcomes compared to radiotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract